Advertisement

BMRA

Biomerica, Inc.

Healthcare · USD

Set alert

Price alert · BMRA

All alert types
1.72 USD -0.02 -1.15%
As of Oct 30, 2026 Extended hours 1.74 +1.16%
Bid
1.71 × 2
Ask
1.74 × 2
1.68 Day range 1.74
1.49 52-week range 2.88
YTD
-31.75%
1 year
-37.68%
Open
1.70
Prev close
1.74
Mkt cap
7.91M
Vol
10.22K
Avg vol
71.60K
EPS
-1.64
P/E
0.00
Div yield
0.00%
More statistics
Low
1.68
High
1.74
Forward P/E
0.71
Beta
-1.14
Short ratio
0.76
Inst. own
12.36%
Dividend
0.00
Ex-div date
Earnings
Jan 21, 2025
50-d avg
0.3326
200-d avg
0.48235
1y target
0.00

2Y chart

Chart tools
Interval
BMRA two-year price chart1.453.635.817.9810.2Oct 24Mar 25Aug 25Jan 26Jun 26Oct 26

Key statistics

Market cap
4.68M
Enterprise value
2.58M
Trailing P/E
0.00
Forward P/E
0.71
PEG ratio
0.00
Price / sales
0.85
Price / book
0.87
EPS (TTM)
-0.37
Beta
-1.14
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-111.85%
Revenue (TTM)
5.51M
Revenue growth
5.50%
Free cash flow
-2.66M
Total cash
2.82M
Total debt
707.00K
Return on equity
-76.48%
Shares outstanding
16.82M
Short % of float
9.13%
50-day average
0.3326
200-day average
0.48235

Analyst view

Consensus: none

Price target (mean) 0.00

Next earnings

Jan 21, 2025

Expected Jan 21, 2025. Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
BMRA Revenue — quarterly 1.26M
2023-Q2 20222023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20262026-Q4 20262027-Q1 2026
BMRA Net income — quarterly -1.23M
2023-Q2 20222023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20262026-Q4 20262027-Q1 2026
BMRA EPS — quarterly -0.37
2023-Q2 20222023-Q3 20232023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20242024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20252025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20262026-Q4 20262027-Q1 2026

Earnings

BMRA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 21, 2025Nov 1, 20240.00———
Oct 15, 2024Aug 1, 20240.00-0.08——
Aug 28, 2024May 1, 20240.00-0.09——
Apr 12, 2024Feb 1, 20240.00-0.11——
Jan 16, 2024Nov 1, 20230.00-0.09——
Oct 12, 2023Aug 1, 20230.00-0.07——

Upgrades / downgrades

BMRA analyst upgrades and downgrades
DateFirmActionFromTo
Oct 19, 2020Aegis Capitalmain—Buy
Sep 4, 2020Aegis Capitalmain—Buy
Aug 21, 2020Aegis Capitalinit—Buy
Dec 17, 2018B. Riley SecuritiesmainBuyBuy

About Biomerica, Inc.

Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications, as well as to measure the levels of specific bacteria, hormones, antibodies, antigens, and other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for treating gastrointestinal diseases and food intolerances, as well as various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also involved in the development of InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and hp+detect, a H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops, markets, and sells COVID-19 diagnostic tests to indicate if a person has been infected by COVID-19. The company was incorporated in 1971 and is headquartered in Irvine, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on BMRA — it syncs with the Stock Master app.

Insider holders

BMRA insider holders
InsiderRelationLatest transactionDateShares held
BARBIERI ALLENOfficer and DirectorStock Award(Grant)Dec 12, 2024188,337
COSTE CATHERINEDirectorStock Award(Grant)Dec 12, 2024128,790
EMERSON JANEDirectorStock Award(Grant)Dec 12, 2024156,000
IRANI ZACKARY SChief Executive OfficerStock Award(Grant)Dec 12, 20241,270,560
LU GARYChief Financial OfficerStock Award(Grant)Dec 12, 2024155,000
MOATAZEDI DAVIDDirectorStock Award(Grant)Dec 12, 202485,000

Institution ownership

BMRA institution ownership
Holder% heldSharesValueReported
Granahan Investment Management LLC3.14%527,461146.63KSep 29, 2024
Russell Investments Group, Ltd.1.34%225,43562.67KSep 29, 2024
Vanguard Group Inc1.00%169,01046.98KSep 29, 2024
Blackrock Inc.0.89%149,08141.44KSep 29, 2024
Geode Capital Management, LLC0.74%124,36334.57KSep 29, 2024
UBS Group AG0.55%91,69225.49KSep 29, 2024

Fund ownership

BMRA fund ownership
Holder% heldSharesValueReported
JNL Series Trust-JNL/Multi Manager Small Cap GrowthFd1.26%211,73658.86KSep 29, 2024
Vanguard Extended Market Index Fund1.00%169,01046.98KSep 29, 2024
USAA Mutual Fund Tr-Small Cap Stock Fund0.49%81,78422.73KJul 30, 2024
Fidelity Extended Market Index Fund0.47%78,87321.93KOct 30, 2024
Perritt Ultra MicroCap Fund0.42%70,00019.46KJul 30, 2024
Fidelity Series Total Market Index Fund0.12%19,8385.51KOct 30, 2024
Advertisement